Bristol-Myers Squibb: Cardiomyopathies trials

The registry lists 10 Cardiomyopathies studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 3Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)RecruitingNCT07541833
• Real-world Patient Reported Outcomes Among Patients Treated With CamzyosRecruitingNCT06551129
• A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyRecruitingNCT06146660
• Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesTerminatedNCT04572893Phase 2Results posted
• A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction TherapyCompletedNCT04349072Phase 3Results posted
• Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERCompletedNCT03496168Phase 2Results posted
• Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyCompletedNCT03470545Phase 3Results posted
• A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)CompletedNCT03442764Phase 2Results posted
• A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491CompletedNCT03062956Phase 1
• Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461CompletedNCT02329184Phase 1